About us

Sweet Crosstalk is a multidisciplinary European Training Network (grant agreement No 814102) built to address the challenge of understanding, at a molecular level, how glycans are involved at the human mucosa–microbiota interface, and how this correlates with human well-being. Research into the human microbiome has reshaped the paradigm of our health and disease. In order to advance further, the time has arrived to understand it at a molecular level. Glycans dominate the microbiota-host interface and are thus ideally positioned to modulate these complex interactions. The research strategy of the Sweet Crosstalk programme focuses on optimal synergy between chemistry and biology. Smart chemistry drives the research to get a molecular-level grip on the role of these glycocodes and their interacting proteins, and advances in biology directs the research. The high quality and credibility of our consortium is ensured by a strong private-public partnership with complementary expertise ranging from chemical synthesis, biochemistry, structural biology to microbiology and cell biology. Our 7 academic groups are all renowned leaders in the glycoscience and microbiome fields, whereas the complementary 4 companies are specialized in glycan-based diagnostics and prophylactic therapies. This unique combination of scientific excellence and industry know-how covers the entire process from obtaining fundamental insight to the development of innovative early diagnostics and glycotherapeutics. Sweet Crosstalk also represents a unique research platform that will train 15 outstanding Early Stage Researchers to be the new generation of innovative scientists with expert knowledge and skills in interdisciplinary glycoscience and human microbiome research. Our international, intersectoral and interdisciplinary training programme will equip them with the necessary scientific and transferable skills that will make them highly competitive for both top European research institutions and the healthcare/biotech job market.

Wennekes Netherlands

Dr. Tom Wennekes